Showing results (291-300 of 831) with videos related to
Sort By:
Pageof 84
Cancer|June 12, 2009
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phaseYesid Alvarado, Hagop Kantarjian, Susan O'Brien, et al.Cancer|June 22, 2010
Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndromeAmit Lahoti, Hagop Kantarjian, Abdulla K Salahudeen, et al.Leukemia Research|April 6, 2010
Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemiaJean-Marie Bruey, Hagop Kantarjian, Wanlong Ma, et al.Cancer|January 7, 2010
Epstein-Barr virus latent membrane protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic leukemiaJeffrey J Tarrand, Michael J Keating, Apostolia M Tsimberidou, et al.Cancer|December 13, 2005
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapyGautam Borthakur, Hagop Kantarjian, George Daley, et al.Journal of Pathology and Translational Medicine|September 8, 2025
Composite chronic lymphocytic leukemia and mantle cell lymphoma involving the bone marrow: a case report and literature reviewRoksolana Demianets, Susan O'Brien, Khosrow Mahdavi, et al.American Journal of Hematology|October 21, 2004
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experienceBryan Hennessy, Francis Giles, Jorge Cortes, et al.Cancer|January 1, 2009
Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemiaApostolia-Maria Tsimberidou, Constantine Tam, Lynne V Abruzzo, et al.Haematologica|January 25, 2012
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapyNaveen Pemmaraju, Hagop Kantarjian, Jianqin Shan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2011
Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemiaHagop Kantarjian, Susan O'Brien, Elias Jabbour, et al.Pageof 84